Incyte Corp Ltd (INCY): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Incyte ( INCY) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.6%. By the end of trading, Incyte fell $1.61 (-2.5%) to $61.87 on average volume. Throughout the day, 1,861,572 shares of Incyte exchanged hands as compared to its average daily volume of 1,683,400 shares. The stock ranged in price between $61.86-$64.10 after having opened the day at $63.55 as compared to the previous trading day's close of $63.48. Other companies within the Drugs industry that declined today were: Cormedix ( CRMD), down 10.9%, Galectin Therapeutics ( GALT), down 10.8%, Agios Pharmaceuticals ( AGIO), down 9.8% and Prosensa Holding N.V ( RNA), down 7.9%.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. Incyte has a market cap of $10.1 billion and is part of the health care sector. Shares are up 25.4% year to date as of the close of trading on Thursday. Currently there are 12 analysts that rate Incyte a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Incyte as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and generally high debt management risk.

On the positive front, Stemline Therapeutics ( STML), up 39.5%, ImmunoCellular Therapeutics ( IMUC), up 18.9%, Idenix Pharmaceuticals ( IDIX), up 17.1% and Bacterin International Holdings ( BONE), up 16.9% , were all gainers within the drugs industry with Biogen Idec ( BIIB) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids

McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2